Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ: JAZZ )

121.41 +1.18 (+0.98%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
4 Exhilarating Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
The Nasdaq Composite is the only major stock index that hasn't put the 2022 bear market in the rearview mirror. For patient investors, it means bargains still abound. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
3 Cannabis Stocks That Could Be Multibaggers in the Making: February Edition
Don’t miss out, as the following cannabis stocks are severely undervalued and are set to increase sales and make huge profits in 2024. 
Via InvestorPlace
Topics Cannabis
Exposures Cannabis
The Queen Of Marijuana Investing Used Psychology To Launch Her Successful Cannabis Investment Fund
Via Benzinga
Topics Cannabis
Exposures Cannabis
3 Biotech Stocks to Buy on the Dip: February 2024
Here are three biotech stocks to buy that are trading at prices that may not account for potential breakthrough opportunities 
Via InvestorPlace
3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List
These biotech stocks offer investors huge potential in the future. Investors may want to consider these equities to enter the industry. 
Via InvestorPlace
Evaluating Jazz Pharmaceuticals: Insights From 7 Financial Analysts
Via Benzinga
Decoding 6 Analyst Evaluations For Jazz Pharmaceuticals
Via Benzinga
4 Eye-Catching Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
The growth-fueled Nasdaq Composite remains nearly 6% below its all-time high, which means amazing deals can still be found. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for January 2024
Biotech stocks are warming up in January and look to continue upward in 2024 as the economy improves. Here are three to check out. 
Via InvestorPlace
Topics Economy
Exposures Economy
Japanese University Will Research Marijuana's Medical Uses In First-Of-Its-Kind Collaboration With Australian Company
Via Benzinga
Topics Cannabis
Exposures Cannabis
2 Incredible Growth Stocks That Are Screaming Buys for 2024
These healthcare businesses are compelling buys for very different reasons. 
Via The Motley Fool
4 Remarkable Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
The growth-fueled Nasdaq Composite remains 7% below its all-time high, which means bargains can still be found. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Analyst Ratings for Jazz Pharmaceuticals
Via Benzinga
Jazz Pharmaceuticals: Q3 Earnings Insights
Via Benzinga
US Stocks Set To Open Weaker As Traders Eye Key Main Street Events: Analyst Sees Buying Opportunity On 'Stunning' Earnings Expectations
Several market-moving catalysts, including the release of the Fed minutes, a Federal Reserve speech, and JOLTS data, could influence the day's market movement. 
Via Benzinga
Topics Economy
Exposures Interest Rates
7 Growth Stocks Poised to Thrive in a Post-Fed Pivot World
If the Federal Reserve loosens the monetary spigot, these companies could represent the growth stocks to buy now. 
Via InvestorPlace
Topics Economy
Exposures Interest Rates
Jazz Pharmaceuticals' Post-Traumatic Stress Disorder Drug Disappoints In Mid-Stage Study
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced top-line results from the Phase 2 trial of JZP150, an investigational small molecule selective fatty acid amide hydrolase (FAAH) inhibitor, on efficacy... 
Via Benzinga
3 No-Brainer Stocks to Buy With $500 Right Now
You don't need a mountain of cash to build wealth on Wall Street. 
Via The Motley Fool
Japan Approves Marijuana-Derived Medicines, Adopt 7-Year Prison Sentences For Recreational Use
Japan’s Parliament passed a bill Wednesday legalizing medical products derived from cannabis. 
Via Benzinga
Australian MPs Admit They Tried Cannabis, Signaling Policy Reform & Epidiolex For Seizures Approved In Canada
Around 8% of Australians are using medical marijuana either occasionally or regularly, according to a recent survey of 1,000 participants conducted by consumer insights company Antenna, reported... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
3 Top-Rated Biotech Stocks That Analysts Are Loving Now
Investing in biotech stocks can be tricky, but analysts have bullish outlooks on these three, promising companies. 
Via InvestorPlace
Pot Stocks: Values Or Traps?
Pot stocks were the hottest thing around five years ago but after catching a bid during the pandemic, the stocks have now plunged to multi-year lows. 
Via Talk Markets
Topics Cannabis
Exposures Cannabis
3 Biotech Stocks That Could Be Millionaire Makers
Many biotech stocks offer exciting long-term growth prospects. 
Via The Motley Fool
Police Boss Turned Cannabis Reform Advocate, MMJ Legalization In Japan And More Global Updates
Medical Cannabis-Based Epidiolex Advances Through Japan's Legislature Earlier this week, Japanese policymakers gave the green light to a measure to legalize medical products derived from cannabis,... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
3 No-Brainer Stocks to Buy With $200 Right Now
A modest amount of money can go a long way when it's invested in inexpensive, game-changing businesses. 
Via The Motley Fool
7 Healthcare Stocks That Are Poised to Become the Next Unicorns
Discover healthcare stocks with remarkable potential for growth and "unicorn" status in the ever-evolving world of healthcare investments. 
Via InvestorPlace
Cannabis Cash Burn Concerns? Sell These 7 Overbought Stocks Now.
These overbought cannabis stocks are teetring on the edge as the sector is navigating through uncharted waters. 
Via InvestorPlace
Topics Cannabis
Exposures Cannabis
FDA Report On Its 50 Years In Cannabis Research, Signals A Boost In Medical Marijuana Prospects
Researchers with the Food and Drug Administration (FDA) reported Wednesday on the agency’s 50 years of experience with marijuana research. In an article titled “FDA’s 50 
Via Benzinga
Topics Cannabis
Exposures Cannabis Product Safety
Ireland Reimburses Medical Marijuana-Based Drug For Chemotherapy-Induced Nausea And Vomiting
Althea Group Holdings Limited (ASX: AGH), an Australian manufacturer of cannabis-based medicines and recreational cannabis products confirmed that Ireland’s Primary Care Reimbursement... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Europe's High: UK Parents Need NHS Help For Daughter's Seizures, THC MMJ Flowers In Switzerland & More
Luxembourg: Medical Marijuana Shortage Due To Supplier Change 
Via Benzinga
Topics Cannabis Supply Chain
Exposures Cannabis Supply Chain
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback